In a study of 413 men who had undergone radical prostatectomy, the Prolaris® test (Myriad Genetics, Inc.), which analyzes the expression level of 46 CCP genes, effectively stratified patients by risk of biochemical recurrence into low- and intermediate/high-risk subgroup. Specifically, 100% of patients in the study with low-risk Prolaris scores did not experience disease recurrence after five years. Prostate cancer did recur in 50% of the patients in the study with high-risk Prolaris scores. Overall, the Prolaris score was found to enhance clinical parameters currently used in risk assessment and offered independent prognostic information beyond PSA, Gleason grade, and pathologic staging. The authors concluded that the findings may help men and healthcare providers make better informed decisions regarding treatment after radical prostatectomy.
"Better risk assessment tools are needed to predict which men are more likely to have recurrence of their disease, even after undergoing aggressive, local treatment such as a radical prostatectomy," said Peter R. Carroll, M.D., M.P.H., Professor and Chair, Urology, University of California, San Francisco. "These findings demonstrate the ability of the Prolaris test either alone, or in conjunction with pathologic features, to predict which men may have an aggressive form of prostate cancer and are at an increased risk for recurrence.”
Presented by Matthew R. Cooperberg, MD, MPH,1 et al. at the 2012 Genitourinary Cancers Symposium - February 2 - 4, 2012 - San Francisco Marriott Marquis - San Francisco, California
1UCSF Helen Diller Family Comprehensive Cancer Center, Urologic Oncology, San Francisco, CA
Reported for UroToday by Karen Roberts, Medical Writer
Related items:
View Full 2012 GU Cancers Symposium Coverage
